{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:59:52Z","timestamp":1791223192371,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progression\u2010free survival (PFS) is a common primary endpoint in first\u2010line epithelial ovarian cancer (EOC) trials; however, its relationship with overall survival (OS) remains uncertain. The patient\u2010level PFS\u2010OS association among individuals with BRCA wild\u2010type advanced EOC treated with first\u2010line platinum\u2010based chemotherapy was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis pooled patient\u2010level data from first\u2010line advanced EOC historical trials sourced from the Medidata Enterprise Data Store. Eligible patients had BRCA wild\u2010type disease and initiated platinum\u2010based chemotherapy (index date) after primary debulking surgery or as neoadjuvant therapy before planned interval debulking surgery. The PFS\u2010OS association was evaluated using Spearman's correlation (\u03c1) and landmark analyses at prespecified timepoints (9, 12, 15, and 18 months after index).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 487 patients (50.1% aged \u226565 years; 90.1% White; 63.7% International Federation of Gynecology and Obstetrics stage III; 54.6% ECOG\u2010PS 0; 37.3% primary debulking surgery; 53.0% interval debulking surgery; median follow\u2010up 3.4 years), the median PFS and OS were 15.6 months (95% CI, 13.8\u201316.8) and 42.1 months (95% CI, 37.8\u201345.7), respectively. The PFS\u2010OS correlation (\u03c1) was 0.7 (95% CI, 0.6\u20130.8). Across all landmarks, progression\u2010free patients experienced longer subsequent OS; at 15 months, the unadjusted HR was 0.29 (95% CI, 0.22\u20130.37). Associations remained after covariate adjustment and did not vary by best overall response, bevacizumab use, or surgical type\/outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this patient population, PFS demonstrated a consistently moderate, positive association with OS across multiple analytical approaches. These findings provide patient\u2010level evidence that PFS is an informative early endpoint, although additional trial\u2010level evaluations are needed to confirm PFS as a validated surrogate for OS in first\u2010line EOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70630","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:57:16Z","timestamp":1790621836000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progression\u2010free survival and overall survival in the first\u2010line treatment of BRCA wild\u2010type advanced epithelial ovarian cancer: An analysis of patient\u2010level data pooled from historical clinical trials"],"prefix":"10.1002","volume":"132","author":[{"given":"Le","family":"Su","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleen","family":"Ports","sequence":"additional","affiliation":[{"name":"Medidata Solutions, Inc. A Dassault Syst\u00e8mes Company  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Gradinariu","sequence":"additional","affiliation":[{"name":"Medidata Solutions, Inc. A Dassault Syst\u00e8mes Company  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7373-8224","authenticated-orcid":false,"given":"Yahav","family":"Itzkovich","sequence":"additional","affiliation":[{"name":"Medidata Solutions, Inc. A Dassault Syst\u00e8mes Company  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Jain","sequence":"additional","affiliation":[{"name":"Medidata Solutions, Inc. A Dassault Syst\u00e8mes Company  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Yamada","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"Tekin","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-6667","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"e_1_2_11_2_1","article-title":"Cancer Stat Facts: Ovarian Cancer","author":"National Cancer Institute","year":"2026","journal-title":"Surveillance, Epidemiology, and End Results Program"},{"key":"e_1_2_11_3_1","volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay JEM"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940\u20106207.capr\u201019\u20100184"},{"key":"e_1_2_11_6_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 1.2026. NCCN. Accessed March 1 2026.https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf"},{"issue":"11","key":"e_1_2_11_7_1","article-title":"Update on the role of surgery in the management of advanced epithelial ovarian cancer","volume":"18","author":"Straubhar A","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx441"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/953509"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201013\u20102287"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01009"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(15)00086\u20108"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13\u2010s2\u201019"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0b013e3181b9c602"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc\u20102023\u2010004487"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032\u2010017\u20100939\u20109"},{"issue":"4","key":"e_1_2_11_18_1","article-title":"Correlation of progression\u2010free and post\u2010progression survival with overall survival in phase III trials of first\u2010line chemotherapy for advanced epithelial ovarian cancer","volume":"36","author":"Shimokawa M","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918788500"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957\u2010023\u201003027\u20104"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12350\u2010019\u201001624\u2010z"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201017\u20101327"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101704"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201019\u20100226"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1103799"},{"key":"e_1_2_11_26_1","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non\u2010BRCA\u2010mutated advanced ovarian cancer","author":"Harter P","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.04.024"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.43"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1812"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32205"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18939"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00225"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441\u2010025\u201000911\u2010x"},{"key":"e_1_2_11_37_1","volume-title":"FDA\u2010AACR Workshop: Approach to Novel Oncology Endpoint Development","author":"American Association for Cancer Research"},{"key":"e_1_2_11_38_1","volume-title":"Translational Science in Drug Development: Surrogate Endpoints, Biomarkers, and More","author":"Duke\u2010Margolis Center for Health Policy"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70630","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:46:34Z","timestamp":1791222394000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1002\/cncr.70630"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70630","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2026-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70630"}}